These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 33300282)

  • 1. Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta-analysis.
    Avgerinos I; Manolopoulos A; Michailidis T; Kitsios K; Liakos A; Karagiannis T; Dimitrakopoulos K; Matthews DR; Tsapas A; Bekiari E
    Diabetes Obes Metab; 2021 Mar; 23(3):822-831. PubMed ID: 33300282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic literature review and network meta-analysis of sodium-glucose co-transporter inhibitors vs metformin as add-on to insulin in type 1 diabetes.
    Langford BE; Evans M; Haskins-Coulter T; O'Connor M; Cant HEO; Eddowes LA; Edmonds C; Tank A
    Diabetes Obes Metab; 2020 Jan; 22(1):39-50. PubMed ID: 31468649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials.
    Zaccardi F; Dhalwani NN; Dales J; Mani H; Khunti K; Davies MJ; Webb DR
    Diabetes Obes Metab; 2018 Apr; 20(4):985-997. PubMed ID: 29205774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of sodium-glucose cotransporter (SGLT) inhibitors in addition to insulin therapy on glucose control and safety outcomes in adults with type 1 diabetes: A meta-analysis of randomized controlled trials.
    Lu J; Tang L; Meng H; Zhao J; Liang Y
    Diabetes Metab Res Rev; 2019 Oct; 35(7):e3169. PubMed ID: 30974510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis.
    Tsapas A; Karagiannis T; Kakotrichi P; Avgerinos I; Mantsiou C; Tousinas G; Manolopoulos A; Liakos A; Malandris K; Matthews DR; Bekiari E
    Diabetes Obes Metab; 2021 Sep; 23(9):2116-2124. PubMed ID: 34047443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With Type 1 Diabetes: A Network Meta-Analysis.
    Kim YJ; Hwang SD; Lim S
    Front Endocrinol (Lausanne); 2020; 11():553. PubMed ID: 32973680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials.
    Musso G; Gambino R; Cassader M; Paschetta E
    BMJ; 2019 Apr; 365():l1328. PubMed ID: 30967375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy and safety of glucose-lowering drugs in children and adolescents with type 2 diabetes: A systematic review and network meta-analysis.
    Wu S; He Y; Wu Y; Ji Y; Hou L; Liu X; Ge Y; Yu Y; Yu Y; Wei Y; Qian F; Luo Q; Feng Y; Feng Y; Wang J; Huo M; Li H; Xue F; Liu Y
    Front Endocrinol (Lausanne); 2022; 13():897776. PubMed ID: 36034458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A systematic review and network meta-analysis.
    Hussein H; Zaccardi F; Khunti K; Davies MJ; Patsko E; Dhalwani NN; Kloecker DE; Ioannidou E; Gray LJ
    Diabetes Obes Metab; 2020 Jul; 22(7):1035-1046. PubMed ID: 32077218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials.
    Li CX; Liu LY; Zhang CX; Geng XH; Gu SM; Wang YQ; Liu H; Xie Q; Liang S
    Front Endocrinol (Lausanne); 2023; 14():1238399. PubMed ID: 37701900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
    Kawalec P; Mikrut A; Łopuch S
    Diabetes Metab Res Rev; 2014 May; 30(4):269-83. PubMed ID: 24829965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis.
    Ma H; Lin YH; Dai LZ; Lin CS; Huang Y; Liu SY
    BMJ Open; 2023 Mar; 13(3):e061807. PubMed ID: 36882248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy of once-weekly semaglutide and SGLT-2 inhibitors in type 2 diabetic patients inadequately controlled with metformin monotherapy: a systematic literature review and network meta-analysis.
    Sharma R; Wilkinson L; Vrazic H; Popoff E; Lopes S; Kanters S; Druyts E
    Curr Med Res Opin; 2018 Sep; 34(9):1595-1603. PubMed ID: 29764222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression.
    Musso G; Sircana A; Saba F; Cassader M; Gambino R
    PLoS Med; 2020 Dec; 17(12):e1003461. PubMed ID: 33373368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.
    Patoulias D; Stavropoulos K; Imprialos K; Katsimardou A; Kalogirou MS; Koutsampasopoulos K; Zografou I; Papadopoulos C; Karagiannis A; Doumas M
    Diabetes Res Clin Pract; 2019 Dec; 158():107927. PubMed ID: 31733280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis.
    Avgerinos I; Michailidis T; Liakos A; Karagiannis T; Matthews DR; Tsapas A; Bekiari E
    Diabetes Obes Metab; 2020 Mar; 22(3):335-345. PubMed ID: 31637820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: A network meta-analysis.
    Tang H; Li G; Zhao Y; Wang F; Gower EW; Shi L; Wang T
    Diabetes Obes Metab; 2018 May; 20(5):1262-1279. PubMed ID: 29369494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials.
    Puckrin R; Saltiel MP; Reynier P; Azoulay L; Yu OHY; Filion KB
    Acta Diabetol; 2018 May; 55(5):503-514. PubMed ID: 29484489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
    Tsapas A; Avgerinos I; Karagiannis T; Malandris K; Manolopoulos A; Andreadis P; Liakos A; Matthews DR; Bekiari E
    Ann Intern Med; 2020 Aug; 173(4):278-286. PubMed ID: 32598218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.